1-p-tolyl-cyclopropanecarbonyl chloride | 916923-19-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-p-tolyl-cyclopropanecarbonyl chloride
• 英文别名: 1-(4-Methylphenyl)cyclopropanecarbonyl chloride；1-(4-methylphenyl)cyclopropane-1-carbonyl chloride
• CAS: 916923-19-8
• 化学式: C₁₁H₁₁ClO
• 分子量: 194.661
• InChiKey: XZBINZCNADGVHM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2916399090

反应信息

• 作为反应物：
  描述：

  1-p-tolyl-cyclopropanecarbonyl chloride 在 乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-ethyl-1-(4-methylphenyl)cyclopropane-1-carboxamide
  参考文献：
  名称：

  NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION

  摘要：

  公开号：

  EP1105120B1
• 作为产物：
  描述：

  1-(4-甲基苯基)-1-环丙甲酸 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 14.0h， 生成 1-p-tolyl-cyclopropanecarbonyl chloride
  参考文献：
  名称：

  蛋白质-配体相互作用中卤素键的系统研究

  摘要：

  卤素键触发活性：通过将芳环H原子与Cl，Br和I交换，可以观察到一系列共价的人组织蛋白酶L抑制剂的结合亲和力增加，Cl，Br和I与S3口袋中的Gly61的CO基团进行卤素键合酶。相反，氟强烈避免卤素键（参见方案）。卤素键的强距离和角度依赖性已被证实适用于生物系统。

  DOI：

  10.1002/anie.201006781

文献信息

• Palladium-Catalyzed Remote <i>meta</i>-C–H Bond Deuteration of Arenes Using a Pyridine Template
  作者：Hui Xu、Min Liu、Ling-Jun Li、Ya-Fang Cao、Jin-Quan Yu、Hui-Xiong Dai

  DOI：10.1021/acs.orglett.9b01784

  日期：2019.6.21

  deuteration of a series of substrates, including phenylacetic acids, hydrocinnamic acid, benzylphosphonate, benzylsulfonate, and benzyl and phenyl ethyl alcohol ester, is developed by using a pyridine-based directing template. The template is installed into the substrate through a practical ester linkage. Under mild reaction conditions, a variety of phenylacetic acids containing alkyl, methoxyl, and halo substituents

  钯催化的一系列底物的间选择性CH氘化反应是通过使用吡啶基导向模板开发的，这些底物包括苯乙酸，氢肉桂酸，苄基膦酸酯，苄基磺酸酯以及苄基和苯基乙醇酯。通过实用的酯键将模板安装到基材中。在温和的反应条件下，各种含有烷基，甲氧基和卤素取代基的苯乙酸在反应中是相容的，导致在间位高水平的D掺入。
• Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
  申请人：Amari Gabriele

  公开号：US20080015226A1

  公开（公告）日：2008-01-17

  The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridynyl alkylene alcohols, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

  该发明涉及磷酸二酯酶4（PDE4）酶的抑制剂。更具体地，该发明涉及1-苯基-2-吡啶基烷基醇衍生物化合物，制备这种化合物的方法，含有它们的组合物以及它们的治疗用途。
• Discovery of 2-[1-(4-Chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic Acid (PSI-421), a P-Selectin Inhibitor with Improved Pharmacokinetic Properties and Oral Efficacy in Models of Vascular Injury
  作者：Adrian Huang、Alessandro Moretto、Kristin Janz、Michael Lowe、Patricia W. Bedard、Steve Tam、Li Di、Valerie Clerin、Natalia Sushkova、Boris Tchernychev、Desiree H. H. Tsao、James C. Keith、Gray D. Shaw、Robert G. Schaub、Qin Wang、Neelu Kaila

  DOI：10.1021/jm9013696

  日期：2010.8.26

  Previously, we reported the discovery of PSI-697 (1a), a C-2 benzyl substituted quinoline salicylic acid-based P-selectin inhibitor. It is active in a variety of animal models of cardiovascular disease. Compound 1a has also been shown to be well tolerated and safe in healthy volunteers at doses of up to 1200 mg in a phase 1 single ascending dose study. However, its oral bioavailability was low. Our goal was to identify a back up compound with equal potency, increased solubility, and increased exposure. We expanded our structure activity-studies in this series by branching at the alpha position of the C-2 benzyl side chain and through modification of substituents on the carboxylic A-ring of the quinoline. This resulted in discovery of PSI-421 with marked improvement in aqueous solubility and pharmacokinetic properties. This compound has shown oral efficacy in animal models of arterial and venous injury and was selected as a preclinical development compound for potential treatment of such diseases as atherosclerosis and deep vein thrombosis.
• Maier, Ludwig; Diel, Peter J., Phosphorus, Sulfur and Silicon and the Related Elements, 1991, vol. 62, # 1.4, p. 15 - 28
  作者：Maier, Ludwig、Diel, Peter J.

  DOI：——

  日期：——
• Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 blockers
  作者：Shengde Wu、Andrew Fluxe、Jim Sheffer、John M. Janusz、Benjamin E. Blass、Ron White、Chris Jackson、Richard Hedges、Michael Murawsky、Bin Fang、Gina M. Fadayel、Michelle Hare、Laurent Djandjighian

  DOI：10.1016/j.bmcl.2006.09.021

  日期：2006.12

  A novel class of tetrazole-derived Kv1.5 blockers is disclosed. In in vitro studies, several compounds had IC(50)s ranging from 180 to 550 nM. In vivo studies indicated that compounds 2f and 2j increased right atrial ERP about 40% without affecting ventricular ERP. (c) 2006 Elsevier Ltd. All rights reserved.